LOVFF (Cannara Biotech) Change In Payables And Accrued Expense : $1.08 Mil (TTM As of Feb. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Change In Payables And Accrued Expense?

Cannara Biotech's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2025 was $-2.23 Mil. It means Cannara Biotech's Accounts Payable & Accrued Expense declined by $2.23 Mil from Nov. 2024 to Feb. 2025 .

Cannara Biotech's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2024 was $2.40 Mil. It means Cannara Biotech's Accounts Payable & Accrued Expense increased by $2.40 Mil from Aug. 2023 to Aug. 2024 .

Cannara Biotech Change In Payables And Accrued Expense Historical Data

The historical data trend for Cannara Biotech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Change In Payables And Accrued Expense Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

0.39

1.95

1.77

4.06

2.40

Cannara Biotech Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															1.79	1.89	0.27	1.16	-2.23

Cannara Biotech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.08 Mil.

Cannara Biotech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

8CB0:Germany LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .